17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.
48 citations
,
September 2013 in “Oncologist” This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
52 citations
,
May 2013 in “Supportive Care in Cancer” Scalp cooling significantly reduces hair loss in chemotherapy patients.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” This correspondence comments on the unknown prevalence of permanent alopecia following high-dose docetaxel chemotherapy and highlights the need for further understanding and prevention strategies.
218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
64 citations
,
July 2011 in “Dermatologic Therapy” This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.
57 citations
,
March 2011 in “The American Journal of Dermatopathology” This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.
48 citations
,
September 2010 in “PubMed” This review discusses chemotherapy-induced hair loss, highlighting that topical minoxidil can lessen its severity or duration but not prevent it, and reports no new clinical results.
67 citations
,
May 2010 in “Journal of The American Academy of Dermatology” This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.
61 citations
,
April 2009 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.
28 citations
,
January 2007 in “Dermatology” This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.
114 citations
,
March 2002 in “Current opinion in oncology/Current opinion in oncology, with cancerlit” This review discusses various skin side effects from chemotherapy, noting that they are mainly toxic rather than allergic and often include alopecia, which can cause significant distress to patients.
53 citations
,
May 2001 in “The American journal of the medical sciences” This article reviews common skin eruptions in chemotherapy patients and discusses how recognizing these patterns can help avoid unnecessary changes to cancer treatment; it reports no new clinical results.
275 citations
,
March 1999 in “Journal of The American Academy of Dermatology” This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.
400 citations
,
October 1995 in “Journal of clinical oncology” This review details the preclinical and early clinical activity and side effects of docetaxel, showing its significant effectiveness against various cancers with neutropenia as a major side effect.
